Medical research

Meet BORIS: Possible new culprit in drug-resistant cancer

Like a Russian bot corrupting U.S. elections, or a new prime minister wreaking havoc in the U.K., a protein named BORIS is showing itself to be a malevolent player in some childhood cancers. New research fingers BORIS as ...

Oncology & Cancer

Algorithm based on response, biology guides neuroblastoma therapy

(HealthDay)—Use of a response- and biology-based treatment algorithm for intermediate-risk neuroblastoma is associated with excellent survival and reduces treatment for some patients, according to a study published online ...

Oncology & Cancer

Mathematical tools to study tumors

Researchers from the Department of Cellular Biology at the University of Seville and the Seville Institute of Biomedicine (IBiS), Pablo Vicente and Doctor Luisma Escudero, in close collaboration with the researcher Rebecca ...

Oncology & Cancer

Research finds new Rx target for childhood cancer

Research led by Michael Lan, Ph.D., Professor of Pediatrics and Genetics at LSU Health New Orleans School of Medicine, found that a compound named 5'-iodotubercidin (5'-IT) suppresses the growth of neuroblastoma cells and ...

Medical research

Protein BRCA1 as a stress coach

Anyone who has ever studied the molecular basis of breast cancer will probably have heard of BRCA1, a protein that protects the cells of breast tissue against cancer. Surprisingly, this protein can also have the opposite ...

page 1 from 12

Neuroblastoma

Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence of about 650 new cases per year in the US. Close to 50 percent of neuroblastoma cases occur in children younger than two years old. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system or SNS. It most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.

Neuroblastoma is one of the few human malignancies known to demonstrate spontaneous regression from an undifferentiated state to a completely benign cellular appearance.

A disease exhibiting extreme heterogeneity, neuroblastoma is stratified into three risk categories: low, intermediate, and high risk. Low-risk disease is most common in infants and highly curable with observation only or surgery, whereas high-risk disease is difficult to cure even with the most intensive multi-modal therapies available.

Note: Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. However, since it is not a sympathetic nervous system malignancy it is a distinct clinical entity and is not to be confused with neuroblastoma.

This text uses material from Wikipedia, licensed under CC BY-SA